<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We investigated the incidence of secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> in patients treated with first-line high-dose chemotherapy (HDCT) plus autologous stem cell transplantation (PBSCT) for advanced <z:e sem="disease" ids="C0153594" disease_type="Neoplastic Process" abbrv="">testicular cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Three hundred and twenty-three patients who were entered into two consecutive prospective Phase-II studies of the German <z:e sem="disease" ids="C0153594" disease_type="Neoplastic Process" abbrv="">Testicular Cancer</z:e> Study Group were analyzed </plain></SENT>
<SENT sid="2" pm="."><plain>A total of 221 patients had received <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-VIP containing <z:chebi fb="2" ids="27899">cisplatin</z:chebi>, ifosfamide, and <z:chebi fb="0" ids="4911">etoposide</z:chebi> and 102 patients were treated with Tax-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-VIP containing <z:chebi fb="2" ids="27899">cisplatin</z:chebi>, ifosfamide, <z:chebi fb="0" ids="4911">etoposide</z:chebi>, and paclitaxel, each cycle supported by autologous PBSCT </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Patients had received a median cumulative <z:chebi fb="0" ids="4911">etoposide</z:chebi> dose of 4.9 g/m(2) (range, 2.2-9.4 g/m(2)) </plain></SENT>
<SENT sid="4" pm="."><plain>The median follow-up duration for <z:hpo ids='HP_0000001'>all</z:hpo> patients was 36 months (range, 0-128) with a median follow up time of 50 months (range, 0-128) for patients surviving at least 1 year after therapy </plain></SENT>
<SENT sid="5" pm="."><plain>One patient developed a secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) involving a chromosomal translocation t(11;19)(q23;p13.3) 24 months after the start of chemotherapy resulting in a cumulative incidence of 0.48% [95% confidence interval (CI) 0-1.42] </plain></SENT>
<SENT sid="6" pm="."><plain>Additionally, two patients with primary mediastinal <z:e sem="disease" ids="C0740345" disease_type="Neoplastic Process" abbrv="">germ cell cancer</z:e> developed a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>No <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> had occurred </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: HDCT including high-dose <z:chebi fb="0" ids="4911">etoposide</z:chebi> with autologous PBSCT as first-line therapy for advanced <z:e sem="disease" ids="C0153594" disease_type="Neoplastic Process" abbrv="">testicular cancer</z:e> was associated with an acceptably low risk of developing secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>